Last reviewed · How we verify
Tramadol OAD
Tramadol is an opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.
Tramadol is an opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief. Used for Moderate to moderately severe chronic pain.
At a glance
| Generic name | Tramadol OAD |
|---|---|
| Sponsor | Labopharm Inc. |
| Drug class | Opioid analgesic with norepinephrine-serotonin reuptake inhibition |
| Target | Mu opioid receptor; norepinephrine transporter; serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Tramadol works through dual mechanisms: it acts as a weak mu opioid receptor agonist and simultaneously inhibits the reuptake of norepinephrine and serotonin in the central nervous system. The OAD (once-a-day) formulation is an extended-release version designed to provide sustained analgesia over 24 hours with a single daily dose, improving patient compliance compared to immediate-release formulations.
Approved indications
- Moderate to moderately severe chronic pain
Common side effects
- Nausea
- Dizziness
- Constipation
- Headache
- Somnolence
- Vomiting
- Seizures
Key clinical trials
- PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects (PHASE1)
- Study of Two Tramadol Contramid® OAD 300 mg Controlled-Release Tablets From Two Different Manufacturing Sites Following a 300 mg Dose in Healthy Subjects Under Fasting and Fed Conditions (PHASE1)
- A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up (PHASE3)
- A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day (PHASE2)
- An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee (PHASE3)
- Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg (PHASE1)
- A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tramadol OAD CI brief — competitive landscape report
- Tramadol OAD updates RSS · CI watch RSS
- Labopharm Inc. portfolio CI